Gliknik Inc
Small molecule drugs for immune disorders
- Sector
- Biotech
- Headquarters
- BALTIMORE, MD
- Founded
- 2007
- Latest Form D
- $11M, Aug 2025
- Total capital
- $36.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $35.1M
- 9 Form D · last Aug 2025
- 14 months since last filing
- Federal contracts
- $1M
- 2 awards · Health and Human S
- Rank in Biotech#187 of 4373
- Granted patents
- 16
- 24 pending · first 2016
- Rank in peer group#105 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 9th filing$11M
- Private capital raisedForm D · SEC · 8th filing$2M
- Private capital raisedForm D · SEC · 7th filing$5.4M
- Private capital raisedForm D · SEC · 6th filing$4.3M
- Private capital raisedForm D · SEC · 5th filing$2.8M
- Private capital raisedForm D · SEC · 4th filing$4.8M
- Federal contractHealth and Human S · TAS::75 0849::TAS; SBIR Topic 255, Phase II "a Stradobody Directed Against Low Expressing Tumor Antigens"$869K
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$850K
- Private capital raisedForm D · SEC · 1st filing$1.9M
Show 1 earlier federal award
- Federal contractHealth and Human S · Biomedical (basic)$150K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
11months
from Gliknik Inc’s first federal award to its first private round.
- First federal award · Sep 2009
- Health and Human S · $150K
- First Form D · Aug 2010
- $1.9M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#105 · top 7%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- David S. BlockResearcherExecutive Officer, DirectorLinked by 6 patents
- Scott Eric StromeResearcherDirectorLinked by 1 patent
- Charles PolskyDirectorNamed in SEC Form D filings
- David V. BroserDirectorNamed in SEC Form D filings
- Elizabeth S. BlockExecutive OfficerNamed in SEC Form D filings
- Geeta A. VemuriDirectorNamed in SEC Form D filings
Show all 16 people
- Joseph S. KleinDirectorNamed in SEC Form D filings
- Joseph Klein, IIIDirectorNamed in SEC Form D filings
- Kyle RusconiDirectorNamed in SEC Form D filings
- Mark A. LernerDirectorNamed in SEC Form D filings
- Paul S. FreidmanDirectorNamed in SEC Form D filings
- Paul A. FriedmanDirectorNamed in SEC Form D filings
- Raymond S. SchinaziDirectorNamed in SEC Form D filings
- Raymond S. ShinaziDirectorNamed in SEC Form D filings
- Richard LernerDirectorNamed in SEC Form D filings
- Richard S. LevyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 16 granted of 40- PendingManufacturing Optimization Of GL-2045, A Multimerizing StradomerUSPTOApplication 18971971
- GrantedMethods Of Treating Inflammatory Disorders With Multivalent Fc CompoundsUSPTOUS 12,337,026
- GrantedManufacturing Optimization Of GL-2045, A Multimerizing StradomerUSPTOUS 12,195,499
Show all 40 patent records
- Manufacturing Optimization Of GL-2045, A Multimerizing StradomerOct 23, 2025 · Application 18971971Pending
- Methods Of Treating Inflammatory Disorders With Multivalent Fc CompoundsJun 24, 2025 · US 12,337,026Granted
- Manufacturing Optimization Of GL-2045, A Multimerizing StradomerJan 14, 2025 · US 12,195,499Granted
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Complement BindingJan 9, 2025 · Application 18887409Pending
- FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONSNov 21, 2024 · Application 18794852Pending
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Complement BindingOct 22, 2024 · US 12,122,836Granted
- FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONSSep 10, 2024 · US 12,084,482Granted
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Fc Receptor BindingAug 8, 2024 · Application 18162308Pending
- Manufacturing Optimization Of GL-2045, A Multimerizing StradomerOct 24, 2023 · US 11,795,193Granted
- ACE2-FC Fusion Proteins And Methods Of UseAug 3, 2023 · Application 18002935Pending
- ACE2 Fc Fusion Proteins And Methods Of UseJun 15, 2023 · Application 18063311Pending
- Methods Of Treating Inflammatory Disorders With Multivalent Fc CompoundsMay 17, 2022 · US 11,331,372Granted
- Manufacturing Optimization Of GL-2045, A Multimerizing StradomerOct 26, 2021 · US 11,155,574Granted
- FUSION PROTEINS OF NATURAL HUMAN PROTEIN FRAGMENTS TO CREATE ORDERLY MULTIMERIZED IMMUNOGLOBULIN Fc COMPOSITIONSSep 14, 2021 · US 11,117,940Granted
- Immunoglobulin Constant Region Fc Receptor Binding AgentsSep 9, 2021 · Application 17163618Pending
- Cysteine-optimized StradomersJun 15, 2021 · US 11,034,775Granted
- Immunoglobulin Constant Region Fc Receptor Binding AgentsMar 9, 2021 · US 10,941,191Granted
- Immunoglobulin Constant Region Fc Receptor Binding AgentsDec 1, 2020 · US 10,851,154Granted
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Fc Receptor BindingDec 26, 2019 · Application 16315871Pending
- Immunoglobulin Constant Region Fc Receptor Binding AgentsFeb 19, 2019 · US 10,208,105Granted
- Molecules With Antigen Binding And Polyvalent Fc Gamma Receptor Binding ActivityApr 5, 2018 · Application 15596178Pending
- Immunoglobulin Constant Region Fc Receptor Binding AgentsMar 27, 2018 · US 9,926,362Granted
- Molecules With Antigen Binding And Polyvalent Fc Gamma Receptor Binding ActivityJun 20, 2017 · US 9,683,044Granted
- Fusion Proteins Comprising IGG2 Hinge DomainsJan 12, 2017 · Application 15258427Pending
- Immunoglobulin Constant Region Fc Receptor Binding AgentsDec 6, 2016 · US 9,512,210Granted
- Immunoglobulin Constant Region Fc Receptor Binding AgentsDec 6, 2016 · US 9,512,208Granted
- Immunoglobulin Constant Region Fc Receptor Binding AgentsSep 29, 2016 · Application 15177061Pending
- Immunoglobulin Constant Region Fc Receptor Binding AgentsNov 13, 2014 · Application 14109384Pending
- Immunoglobulin Constant Region Fc Receptor Binding AgentsApplication 15370675Pending
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Fc Receptor BindingApplication 62365921Pending
- Fusion Proteins Of Human Protein Fragments To Create Hexameric Immunoglobulin Fc CompositionsApplication 62365919Pending
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Complement BindingApplication PCTUS2016043746Pending
- Cysteine Optimized Improvements To Multimerizing StradomersApplication 62350534Pending
- Cysteine Optimized Improvements To Multimerizing StradomersApplication 62346994Pending
- Fusion Proteins Of Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc Compositions With Enhanced Complement BindingApplication 62196478Pending
- Fusion Proteins Of Natural Human Protein Fragments To Create Orderly Multimerized Immunoglobulin Fc CompositionsApplication PCTUS2011045768Pending
- ACE2-FC Fusion Proteins And Methods Of UseApplication 63176959Pending
- Methods Of Using Immunoglobulin AggregatesApplication PCTUS2010034765Pending
- ACE2-FC Fusion Proteins And Methods Of UseApplication 63175851Pending
- ACE2-FC Fusion Proteins And Methods Of UseApplication 63153592Pending
Related companies, and why
- SunFire Biotechnologies LLCSimilar federal contract value in Biotech · $1.1M in contracts
- Molecular Loop Biosciences, Inc.Similar federal contract value in Biotech · $1M in contracts
- OXFORD BIOMEDICAL RESEARCH, INC.Similar federal contract value in Biotech · $1M in contracts
- Flow Pharma, Inc.Similar federal contract value in Biotech · $1.0M in contracts
- SPACE TANGO LLCSimilar federal contract value in Biotech · $998K in contracts
- DIANT PHARMA INCSimilar federal contract value in Biotech · $995K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .